Form 4: Rhythm Pharmaceuticals Executive Exercises Options and Sells Shares

Pamela J. Cramer, Chief Human Resources Officer of Rhythm Pharmaceuticals, executed stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On August 26, 2024, Pamela J. Cramer, the Chief Human Resources Officer of Rhythm Pharmaceuticals, exercised stock options to acquire 3,200 shares of common stock at a price of $19.02 per share.
• Simultaneously, Cramer sold 3,200 shares of common stock at a weighted average price of $50.0056 per share, with individual sales ranging from $50.00 to $50.03.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 10, 2024.
• Following these transactions, Cramer directly owns 13,500 shares of Rhythm Pharmaceuticals common stock and 27,536 stock options.

Sentiment

Score: 5

Explanation: Neutral sentiment as it reflects routine insider transactions under a pre-established plan.

Positives

• The Rule 10b5-1 plan allows insiders to sell shares without being accused of trading on inside information.

Industry Context

Insider transactions are common and closely monitored, with Rule 10b5-1 plans providing a legal framework for pre-planned sales.

Comparison to Industry Standards

• Stock option exercises and sales are a typical part of executive compensation in publicly traded companies like Rhythm Pharmaceuticals.
• The use of Rule 10b5-1 plans is a standard practice among executives at companies such as Amgen, Biogen, and Vertex Pharmaceuticals to avoid insider trading accusations.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares by an executive.

Key Dates